Document Detail


Comparison of serum prostate specific membrane antigen, prostate specific antigen, and free prostate specific antigen levels in radical prostatectomy patients.
MedLine Citation:
PMID:  9210715     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: Higher preoperative prostate specific antigen (PSA) levels are associated with higher pathologic stage and grade in patients undergoing radical prostatectomy (RP). In earlier studies, serum prostate specific membrane antigen (PSMA) elevations were associated with clinical progression and hormone-refractory carcinoma. The goal of this study was to evaluate the serum markers PSMA, free PSA (FPSA), free:total PSA ratio (F:TPSA), and total PSA (PSA) in men undergoing RP. METHODS: Serum was obtained from 63 patients undergoing RP for clinically localized (T1c, T2) prostate carcinoma. Serum PSA and FPSA were determined by Hybritech Tandem-E(R) and Tandem-R(R), respectively, and PSMA was determined by Western blot analysis. Serum values for these markers were compared with the pathologic stage, surgical margin status, Gleason sum, prostate size (as calculated via reconstruction and transrectal ultrasound), tumor size based on pathologic assessment of the whole mount, and World Health Organization (WHO) grade of the prostatectomy specimen. Markers were also compared against demographic information and the patients' age and race. RESULTS: There was a weak correlation between serum PSA and positive surgical margins, higher Gleason sum, and WHO grade (P < 0.05). Receiver operating characteristic curve (ROC) analysis comparing sensitivity and specificity of the markers to positive and negative margins as well as seminal vesicle invasion demonstrated PSA and FPSA predictive ability for seminal vesicle invasion. The area under the curve for PSA and FPSA in this case was 0.7318 and 0.7432, respectively. There was also a weak correlation between the FPSA level and margins, with a low ROC area under the curve of 0.6789. The FPSA cannot distinguish the more advanced stage of disease. There was no significant correlation between F:TPSA and PSMA with regard to the study variables in predicting organ confinement. High PSMA levels only correlated with higher stage and were maximal in pT4a classified disease. CONCLUSIONS: Higher PSA and FPSA levels are likely to be associated with more locally advanced disease. Total PSA was the best marker. However, the cutoff values necessary for significant accuracy between PSA and FPSA are not of clinical usefulness due to the lack of specificity and sensitivity of the markers at those cutoffs. F:TPSA and PSMA levels as currently measured are of limited value in discriminating more aggressive disease in patients with clinically localized CaP.
Authors:
T H Douglas; T O Morgan; D G McLeod; J W Moul; G P Murphy; R Barren; I A Sesterhenn; F K Mostofi
Related Documents :
20303155 - Salvage therapy with bicalutamide 150 mg in nonmetastatic castration-resistant prostate...
20841515 - Retrospective analysis of the consequences of acid suppressive therapy on ketoconazole ...
11172945 - Radiation pneumonitis in lung cancer patients: a retrospective study of risk factors an...
7658545 - Indications for seminal vesicle biopsy and laparoscopic pelvic lymph node dissection in...
15865885 - Optimal role of temozolomide in the treatment of malignant gliomas.
877835 - The value of laparotomy in staging of lymphoma.
Publication Detail:
Type:  Comparative Study; Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.    
Journal Detail:
Title:  Cancer     Volume:  80     ISSN:  0008-543X     ISO Abbreviation:  Cancer     Publication Date:  1997 Jul 
Date Detail:
Created Date:  1997-07-29     Completed Date:  1997-07-29     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  0374236     Medline TA:  Cancer     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  107-14     Citation Subset:  AIM; IM    
Affiliation:
Department of Surgery, Walter Reed Army Medical Center, Washington, DC 20307-5001, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Aged
Antigens, Neoplasm / blood*
Antigens, Surface / blood*
Glutamate Carboxypeptidase II
Humans
Male
Middle Aged
Neoplasm Staging / methods*
Prostate-Specific Antigen / blood*
Prostatectomy
Prostatic Neoplasms / blood*,  pathology,  surgery
ROC Curve
Chemical
Reg. No./Substance:
0/Antigens, Neoplasm; 0/Antigens, Surface; EC 3.4.17.21/Glutamate Carboxypeptidase II; EC 3.4.17.21/glutamate carboxypeptidase II, human; EC 3.4.21.77/Prostate-Specific Antigen

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Vascular endothelial growth factor expression in early stage ovarian carcinoma.
Next Document:  Radical chemoradiotherapy for elderly patients with bladder carcinoma invading muscle.